Connect with us

Health

Ebola: DRC gets 70,000 Ervebo vaccine doses as Bundibugyo outbreak worsens

info

Published

on

Vaccines for homeless western cape vaccination.jpg

MTN ADVERT

The Democratic Republic of the Congo (DRC) has received an initial allocation of 70,000 doses of the Ervebo Ebola vaccine to support the response to the ongoing Bundibugyo virus disease outbreak.

The World Health Organisation (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) disclosed this in a joint statement on Thursday.

The allocation followed a request by the DRC government last week for vaccines from the global Ebola virus disease vaccine stockpile managed by the International Coordinating Group on Vaccine Provision (ICG).

Of the 70,000 doses, 20,000 will be used in a Phase III clinical trial to assess whether Ervebo can protect against Bundibugyo virus, while the remaining 50,000 doses will be administered to frontline and health workers in line with recommendations by the WHO Strategic Advisory Group of Experts on Immunisation (SAGE).

Why the vaccine is being tested

The decision to use part of the allocation in a clinical trial reflects the uncertainty surrounding the effectiveness of Ervebo against Bundibugyo virus.

PT WHATSAPP CHANNEL

Ervebo is a licensed vaccine recommended for use during outbreaks caused by the Zaire species of Ebola virus. The current outbreak in the DRC, however, is caused by Bundibugyo virus, a different species of the Ebola virus.

WHO said it is not yet known whether Ervebo can protect humans against Bundibugyo virus, although early laboratory and animal studies suggest that it may provide some protection.

The Phase III trial is therefore expected to generate evidence on whether the vaccine can offer protection against the virus and help guide future decisions on its use during similar outbreaks.

WHO said people offered the vaccine, whether as part of the trial or outside it, must be informed about the potential risks, benefits and limitations of using Ervebo against Bundibugyo virus and must provide informed consent.

Outbreak spread

According to the latest WHO disease outbreak update, 4,665 confirmed cases and 2,184 deaths had been reported as of 12 August.

The outbreak has expanded from the Mongbwalu health zone in Ituri Province to 54 health zones across six provinces: Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo and Bas-Uélé.

WHO described the outbreak as being in a phase of intense transmission and said it was the largest Ebola outbreak ever reported in the DRC.

The outbreak was declared on 15 May and has been driven by factors including population movement, insecurity, artisanal mining activities and cross-border travel involving Uganda and South Sudan.

The scale of the outbreak has consequently increased pressure on health authorities and researchers to deploy available interventions while developing tools specifically suited to the Bundibugyo virus.

Vaccine development

In July, PREMIUM TIMES reported that the first human clinical trial of an experimental Bundibugyo Ebola vaccine had begun at the University of Oxford.

The Phase I trial, known as BD-Ebov, is assessing the safety of the experimental ChAdOx1 BDBV vaccine and its ability to stimulate immune responses in healthy adults.

The vaccine was developed by the University of Oxford’s Oxford Vaccine Group and Pandemic Sciences Institute in collaboration with the Serum Institute of India and the Coalition for Epidemic Preparedness Innovations (CEPI).

Unlike Ervebo, which is licensed for use against Zaire ebolavirus, ChAdOx1 BDBV was specifically designed to target Bundibugyo virus.

The development of a vaccine specifically targeting the virus is considered important because there is currently no approved vaccine specifically for Bundibugyo virus.

The use of Ervebo in the current outbreak could therefore serve a dual purpose; providing protection to health workers who are at high risk of exposure while generating evidence on whether an existing Ebola vaccine can provide protection against another species of the virus.

WHO’s technical advisory group on candidate vaccine prioritisation recently recommended that Ervebo be included in a randomised clinical trial during the ongoing DRC outbreak following a review of emerging evidence on its potential cross-protection against Bundibugyo virus.

Community response

Beyond the vaccines, WHO and Africa CDC said the success of the response would also depend on the involvement of communities affected by the outbreak.

The two organisations welcomed the allocation of the vaccines and supported the DRC’s focus on a community-led approach, which they said would give communities a central role in the response.

Such an approach, they said, would help protect affected populations, save lives and contain transmission while ensuring that people receiving the vaccine understand its potential benefits and limitations.

The ICG partners are WHO, the International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières (MSF) and United Nations Children’s Fund (UNICEF), while Gavi, the Vaccine Alliance, provides funding for the global vaccine stockpile.

WHO and Africa CDC said they remained committed to supporting the DRC government to end the outbreak while generating scientific evidence that could strengthen preparedness for future outbreaks.

READ ALSO: DRC Ebola outbreak becomes second-largest on record – WHO

Nigeria’s preparedness

The continued spread of the virus has also raised concerns beyond the DRC because of the potential for cross-border transmission.

Nigeria has subsequently heightened its preparedness, with the Nigeria Centre for Disease Control and Prevention (NCDC) activating its Emergency Operations Centre, strengthening surveillance at points of entry and increasing monitoring across states.

The federal government also identified 21 states and the Federal Capital Territory as being at high risk of Ebola infection following a dynamic risk assessment.

State governments were urged to strengthen surveillance, isolation capacity and infection prevention and control measures.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Drug-resistant bacterial infections kill one million people annually – WHO

info

Published

on

WhatsApp Image 2026 05 18 at 21.41.48.jpeg

The World Health Organisation (WHO) says drug-resistant bacterial infections kill about one million people globally every year, calling for coordinated action across human, animal, food and environmental sectors to curb the growing threat.

Jean-Pierre Nyemazi, Acting Director of the AMR Department at WHO Headquarters, said this at a virtual media conference marking an exhibition at the European Parliament on AMR and its human impact.

The virtual conference preceded the exhibition, “AMR: The Human Stories Behind a Silent Pandemic,” being held at the European Parliament from 28 September to 2 October and featuring stories of people affected by AMR across Europe.

“AMR is taking many lives. One million people die every year due to drug-resistant bacteria alone – that is, two people every minute die of bacterial AMR,” Mr Nyemazi said.

He said the scale of deaths meant that AMR should no longer be treated as a “silent pandemic”, stressing that “we know what works” to prevent and control the threat.

“Preventing infections is the number one priority. This can be done through better vaccination, infection prevention and control, Water, Sanitation and Hygiene (WASH), and improved animal husbandry,” he said.

PT WHATSAPP CHANNEL
Dangote Refinery AD

“All of these work and can prevent AMR.”

Mr Nyemazi said strengthening surveillance, responsible use of antimicrobials, access to quality medicines and diagnostics, and reduction of environmental contamination could also make a difference.

“The tools exist, and the evidence is there, but the cost of inaction is rising. The longer we delay action, the higher the cost becomes,” he said.

He said the One Health approach, which recognises the links between human, animal, plant and environmental health, was essential because drug-resistant pathogens could move across sectors and borders.

According to him, parliamentarians have a critical role in ensuring that national AMR commitments are supported by legislation, financing and accountability.

“The media also plays an indispensable role. Journalists help bring AMR out of scientific circles and into public debate,” he said.

“They raise awareness, combat misinformation, and ensure that AMR remains visible to decision-makers and the public alike.”

He said WHO Member States approved an updated Global Action Plan on AMR at the World Health Assembly in May, providing a framework for combating AMR over the next 10 years through a One Health approach.

Mr Nyemazi said the updated plan placed stronger emphasis on prevention, governance, behavioural change and measurable targets, and that the four Quadripartite organisations developed it jointly.

He said the organisations comprised the Food and Agriculture Organisation (FAO), United Nations Environment Programme (UNEP), WHO and World Organisation for Animal Health (WOAH).

“What is new about the updated Global Action Plan on AMR for the next 10 years is that it is truly multi-sectoral – a genuine One Health plan.

“The previous plan was heavily focused on human health; this time the four Quadripartite organisations worked together and engaged all sectors,” he said.

Mr Nyemazi said a 10 per cent reduction in AMR was achievable through infection prevention and control, vaccination and improved access to quality antimicrobials, with better coordination, education and surveillance capable of delivering further gains.

He also called for investment in new antibiotics, antifungals, phage therapy and other technologies, while stressing the need to preserve existing medicines.

He said there was also a major access problem, with many regions unable to obtain even existing antibiotics.

A member of the European Parliament, Martin Häusling, said excessive antibiotic use in food-producing animals was contributing to the problem, particularly through mass treatment.

“When it comes to food-producing animals, we still use far too many last-resort antibiotics, and we must get away from that,” Mr Häusling said.

He said AMR was a global issue that could affect anyone, adding that it could destroy families and livelihoods.

To tackle it, the parliamentarian said it was important to create public awareness so that parliaments could address the issue properly, adding that the issue was still not taken as seriously as a future challenge should be.

Rob Purdie, an AMR survivor and member of the WHO Task Force of AMR Survivors, said his experience demonstrated the consequences of delayed diagnosis and treatment.

Mr Purdie said an infection that began with a headache eventually progressed to fungal meningitis after he received antibiotics for a condition that had not been properly diagnosed.

READ ALSO: Four Super Eagles stars who could decide Nigeria’s AFCON Qualifier against Guinea-Bissau

He said he eventually spent about $250,000 on hospital costs and had been unable to work for about five years.

“My ability to earn a living was eliminated for about five years in a single-income household where I provided for my wife and two children,” he said.

Mr Purdie said his experience underscored the need to keep AMR visible in public discussions.

“That is why it is so important for those of us who have survived and can speak, to remove the word ‘silent’ from the ‘silent pandemic’,” he said.

(NAN)


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

Plateau: Medical Women Association of Nigeria Marks Older Persons Day with Free Outreach

info

Published

on

FB IMG

 

The Medical Women Association of Nigeria (MWAN) Plateau State, in collaboration with the Plateau State Specialist Hospital, has organised a free medical outreach for persons aged 60 and above in Jos.

The outreach, held to commemorate the 2026 International Day of Older Persons, featured free medical consultations, health talks, eye and ear examinations, blood pressure and blood sugar checks, general health screening and provision of basic medications.

FB IMG

The programme was held on October 2, a day after the official International Day of Older Persons, which is observed globally every October 1.

The 2026 celebration is themed “The Age of Longevity: Rethinking Systems for Longer Lives.”

FB IMG

Speaking during the event, Plateau State Commissioner for Health, Nicholas Ba’amlong, represented by the Director of Medical Services, Dr Stephen Bishmang, reaffirmed the state government’s commitment to strengthening the health system and ensuring access to healthcare regardless of age, status or circumstance.

Bishmang commended MWAN and the Plateau State Specialist Hospital for organising the outreach, noting that collaboration between government, healthcare professionals and civil society organisations could help improve healthcare delivery and the wellbeing of older persons.

FB IMG

State President of MWAN, Sekyen Sana, said the initiative was aimed at addressing the healthcare needs of older persons and helping them live healthier and more fulfilling lives.

She noted that ageing is a natural process and should not necessarily be associated with sickness, stress or emotional difficulties.

Sana said MWAN wants older persons to remain healthy, happy and able to enjoy their lives while encouraging them to pay greater attention to their health.

FB IMG

The Chief Medical Director of Plateau State Specialist Hospital, Professor Christopher Yilgwan, represented by Barnabas Saidu, welcomed the beneficiaries and encouraged them to take advantage of available healthcare services.

He also urged retirees and older persons who had not been enrolled in the state health insurance programme to make enquiries and register so they could access available medical services.

Saidu stressed the importance of regular health checks, noting that medical conditions can be identified and treated more effectively when detected early.

FB IMG

Also speaking, the Plateau State Chairman of the Nigeria Medical Association, Dr Shainan Andrew, pledged continued collaboration with MWAN and other stakeholders to expand healthcare interventions for older persons.

Andrew encouraged the beneficiaries to seek medical advice, ask questions about their health and take advantage of available healthcare services.

One of the beneficiaries, Da Samuel Davou, expressed appreciation to the organisers for providing the free medical services.

The organisers appealed to government agencies, non-governmental organisations, companies and other stakeholders to support similar initiatives to enable more older persons to access healthcare and enjoy healthier lives.

FB IMG FB IMG  FB IMG FB IMG   FB IMG

Continue Reading

Trending